SeaBeLife

SeaBeLife is a biotechnology company developing a series of candidate drugs that block regulated necrosis (or regulated cell death) based on two patented molecular families. The technology has demonstrated its ability to simultaneously block two forms of regulated cell death in vitro and in several in vivo proof-of-concept studies, thereby protecting the affected organs. SeaBeLife protects lives through a new technology that directly blocks programmed cell death in critical situations where severe diseases threaten major organs and no alternative treatments are available.